Products under development
Immunology
- Ongoing project seeking a regulatory submission in the United States.
- Development of a new route of administration.
Haemostasis
Recombinant activated factor VII in haemophilia A & B with inhibitors:
- Clinical development in progress in the United States seeking a label extension.
- Regulatory application in progress in Saudi Arabia, planned in Colombia and Algeria.
LFB has been granted a Marketing Authorisation for CEVENFACTA® (eptacog beta [activated]) in the
European Union, and for SEVENFACT® (another brand name of eptacog beta [activated]) in Mexico,
and in the United States of America. This may make it possible to offer a new therapeutic option to
more patients around the world.
Intensive Care
Fibrinogen:
- Ongoing clinical development activities seeking label extension in Europe.
- Ongoing activities seeking regulatory submission in the United States.
- Development of a new dosage.
The LFB group is conducting several clinical trials in order to register its products, in the fields of immunology, haemostasis and intensive care.
For more information on clinical trials of the products under development, please refer to the following websites:
- International Clinical Trial Registry Platform : http://apps.who.int/trialsearch/
- In United States: https://clinicaltrials.gov/
- In Europe: clinicaltrialsregister.eu/
